133 related articles for article (PubMed ID: 28412548)
1. Internal image anti-idiotypic antibody: A new strategy for the development a new category of prolactin receptor (PRLR) antagonist.
Lan H; Hong P; Li R; L S; Anshan S; Li S; Zheng X
Mol Immunol; 2017 Jul; 87():86-93. PubMed ID: 28412548
[TBL] [Abstract][Full Text] [Related]
2. Development of a new anti-prolactin receptor (PRLR) antibody, F56, which can serve as a PRLR antagonist.
Cui H; Ma YZ; Wang Y; Song M; Zhang H
Int J Biol Macromol; 2017 Feb; 95():1223-1227. PubMed ID: 27829125
[TBL] [Abstract][Full Text] [Related]
3. Different intracellular signalling pathways triggered by an anti-prolactin receptor (PRLR) antibody: Implication for a signal-specific PRLR agonist.
Kan QE; Su Y; Yang H; Man H
Int J Biol Macromol; 2016 Jan; 82():892-7. PubMed ID: 26526176
[TBL] [Abstract][Full Text] [Related]
4. Preparation of a Growth Hormone Receptor/Prolactin Receptor Bispecific Antibody Antagonist Which Exhibited Anti-Cancer Activity.
Chen X; Wu D; Zheng Y; Liu X; Wang J
Front Pharmacol; 2020; 11():598423. PubMed ID: 33362552
[TBL] [Abstract][Full Text] [Related]
5. Development of a Novel, Anti-idiotypic Monoclonal Anti-prolactin Antibody That Mimics the Physiological Functions of Prolactin.
Wang M; Zhang DC; Wang ST; Li ML
Asian-Australas J Anim Sci; 2016 Apr; 29(4):571-9. PubMed ID: 26949959
[TBL] [Abstract][Full Text] [Related]
6. Re-evaluation of the prolactin receptor expression in human breast cancer.
Galsgaard ED; Rasmussen BB; Folkesson CG; Rasmussen LM; Berchtold MW; Christensen L; Panina S
J Endocrinol; 2009 Apr; 201(1):115-28. PubMed ID: 19153125
[TBL] [Abstract][Full Text] [Related]
7. Anti-idiotypic antibody: A new strategy for the development of a growth hormone receptor antagonist.
Lan H; Zheng X; Khan MA; Li S
Int J Biochem Cell Biol; 2015 Nov; 68():101-8. PubMed ID: 26369868
[TBL] [Abstract][Full Text] [Related]
8. The activation and differential signalling of the growth hormone receptor induced by pGH or anti-idiotypic monoclonal antibodies in primary rat hepatocytes.
Li W; Lan H; Liu H; Fu Z; Yang Y; Han W; Guo F; Liu Y; Zhang H; Liu J; Zheng X
Mol Cell Endocrinol; 2013 Aug; 376(1-2):51-9. PubMed ID: 23769824
[TBL] [Abstract][Full Text] [Related]
9. Additive effects of a prolactin receptor antagonist, G129R, and herceptin on inhibition of HER2-overexpressing breast cancer cells.
Scotti ML; Langenheim JF; Tomblyn S; Springs AE; Chen WY
Breast Cancer Res Treat; 2008 Sep; 111(2):241-50. PubMed ID: 17955362
[TBL] [Abstract][Full Text] [Related]
10. Antiidiotypic antibodies raised against anti-prolactin (PRL) antibodies recognize the PRL receptor.
Amit T; Barkey RJ; Gavish M; Youdim MB
Endocrinology; 1986 Feb; 118(2):835-43. PubMed ID: 3002768
[TBL] [Abstract][Full Text] [Related]
11. Preclinical Activity of the Novel Anti-Prolactin Receptor (PRLR) Antibody-Drug Conjugate REGN2878-DM1 in PRLR-Positive Breast Cancers.
Kelly MP; Hickey C; Makonnen S; Coetzee S; Jalal S; Wang Y; Delfino F; Shan J; Potocky TB; Chatterjee I; Andreev J; Kunz A; D'Souza C; Giurleo JT; Nittoli T; Trail PA; Thurston G; Kirshner JR
Mol Cancer Ther; 2017 Jul; 16(7):1299-1311. PubMed ID: 28377489
[TBL] [Abstract][Full Text] [Related]
12. The protein tyrosine kinase P59fyn is associated with prolactin (PRL) receptor and is activated by PRL stimulation of T-lymphocytes.
Clevenger CV; Medaglia MV
Mol Endocrinol; 1994 Jun; 8(6):674-81. PubMed ID: 7935483
[TBL] [Abstract][Full Text] [Related]
13. Functional idiotypic mimicry of an adhesion- and differentiation-promoting site on acetylcholinesterase.
Johnson G; Moore SW
J Cell Biochem; 2004 Apr; 91(5):999-1009. PubMed ID: 15034934
[TBL] [Abstract][Full Text] [Related]
14. A Neutralizing Prolactin Receptor Antibody Whose In Vivo Application Mimics the Phenotype of Female Prolactin Receptor-Deficient Mice.
Otto C; Särnefält A; Ljungars A; Wolf S; Rohde-Schulz B; Fuchs I; Schkoldow J; Mattsson M; Vonk R; Harrenga A; Freiberg C
Endocrinology; 2015 Nov; 156(11):4365-73. PubMed ID: 26284426
[TBL] [Abstract][Full Text] [Related]
15. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer.
Damiano JS; Rendahl KG; Karim C; Embry MG; Ghoddusi M; Holash J; Fanidi A; Abrams TJ; Abraham JA
Mol Cancer Ther; 2013 Mar; 12(3):295-305. PubMed ID: 23270929
[TBL] [Abstract][Full Text] [Related]
16. Prolactin receptor signaling: A novel target for cancer treatment - Exploring anti-PRLR signaling strategies.
Standing D; Dandawate P; Anant S
Front Endocrinol (Lausanne); 2022; 13():1112987. PubMed ID: 36714582
[TBL] [Abstract][Full Text] [Related]
17. Preparation and identification of an anti-idiotypic antibody antagonist (FG8) for EGFR that shows potential activity against liver cancer cells.
Wang Y; He F; Zhang H; Cao Y; Zhang Y; Ling Y; Rehati A
Biotechnol Lett; 2021 Feb; 43(2):369-382. PubMed ID: 33141321
[TBL] [Abstract][Full Text] [Related]
18. [Production of phage-displayed anti-idiotypic antibody single chain variable fragments to MG7 monoclonal antibody directed against gastric carcinoma].
He F; Nie Y; Han Z
Zhonghua Yi Xue Za Zhi; 2001 Jan; 81(1):33-6. PubMed ID: 11798849
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal anti-idiotype antibody bearing the internal image of nasopharyngeal carcinoma associated antigen.
Li G; Hu J; Zhou G; Zhu J; Sun Q
Chin Med J (Engl); 2001 Sep; 114(9):962-6. PubMed ID: 11780392
[TBL] [Abstract][Full Text] [Related]
20. Characterization of ductal and lobular breast carcinomas using novel prolactin receptor isoform specific antibodies.
Ginsburg E; Alexander S; Lieber S; Tarplin S; Jenkins L; Pang L; Heger CD; Goldsmith P; Vonderhaar BK
BMC Cancer; 2010 Dec; 10():678. PubMed ID: 21144038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
